Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study
of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy. Enrollment
will include all patients who started Nilotinib between January 2005 and December 2012.
Patients will be followed for 4 years since treatment start. After this time, survival data,
disease status and treatment will be recorded at 6-months-interval. This study will help the
definition of guidelines for a proper management of Nilotinib in any-phase CML patients.